The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA‐HF study-Reference-Cited by-同舟云学术

The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA‐HF study

Published:2020-06-15 Issue:8 Volume:36 Page:
ISSN:1520-7552
Container-title:Diabetes/Metabolism Research and Reviews
language:en
Short-container-title:Diabetes Metab Res Rev

Author:

Carbone Salvatore¹²^ORCID,Billingsley Hayley E.¹²,Canada Justin M.²,Bressi Edoardo²,Rotelli Brando²,Kadariya Dinesh²,Dixon Dave L.³^ORCID,Markley Roshanak²,Trankle Cory R.²,Cooke Richard²,Rao Krishnasree²,Shah Keyur²,Medina de Chazal Horacio²,Chiabrando Juan Guido²,Vecchié Alessandra²,Dell Megan²,L. Mihalick Virginia²,Bogaev Roberta⁴,Hart Linda⁴,Van Tassell Benjamin W.³,Arena Ross⁵⁶,Celi Francesco S.⁷,Abbate Antonio²

Affiliation:

1. Department of Kinesiology & Health Sciences, College of Humanities & Sciences Virginia Commonwealth University Richmond Virginia USA

2. Division of Cardiology, Department of Internal Medicine, VCU Pauley Heart Center Virginia Commonwealth University Richmond Virginia USA

3. Department of Pharmacotherapy and & Outcomes Science, School of Pharmacy Virginia Commonwealth University Richmond Virginia USA

4. Advanced Heart Failure Center Bon Secours Heart & Vascular Institute Richmond Virginia USA

5. Department of Physical Therapy, College of Applied Health Sciences University of Illinois at Chicago Chicago Illinois USA

6. TotalCardiology Research Network Calgary Alberta Canada

7. Division of Endocrinology Diabetes and Metabolism, Department of Internal Medicine Virginia Commonwealth University Richmond Virginia USA

Funder

Janssen Research and Development

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/dmrr.3335

Reference32 articles.

1. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes

2. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

3. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

4. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

5. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of sodium–glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta‐analysis;European Journal of Heart Failure;2024-01-18

2. Two years with GIOIA ‘Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes’: A prospective, multicentre, quasi‐experimental study on sodium‐glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors in diabetes clinical practice;Diabetes, Obesity and Metabolism;2024-01-17

3. SGLT2 inhibitors in Patients Admitted for Acute Heart Failure: The Earlier the Better;The American Journal of Cardiology;2023-12

4. Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus;Pharmaceutics;2023-10-25

5. Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies;Cardiovascular Diabetology;2023-09-02